Ozmosi | Polyethyleneglycol-3350 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Polyethyleneglycol-3350

Alternative Names: polyethyleneglycol-3350, polyethyleneglycol3350, polyethyleneglycol 3350
Clinical Status: Inactive
Latest Update: 2013-02-07
Latest Update Note: Clinical Trial Update

Product Description

Polyethylene glycol 3350 is used to treat occasional constipation. (Sourced from: https://medlineplus.gov/druginfo/meds/a603032.html)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Braintree Laboratories
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Constipation

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT00153153

851-CR1

P4

Completed

Constipation

2004-12-01

2019-03-21

Treatments

NCT00164125

851-CR3

P4

Completed

Constipation

2004-11-01

2019-03-21

Treatments

NCT00153140

851-ZCC

P4

Completed

Constipation

2004-10-01

2019-03-21

Treatments

NCT00153114

NCT00153114

P4

Completed

Constipation

2004-09-01

2019-03-21

Treatments

NCT00153127

NCT00153127

P4

Completed

Constipation

2004-09-01

2019-03-21

Treatments

Recent News Events

Date

Type

Title